Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) EPS (Weighted Average and Diluted) (2022 - 2024)

Adial Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$65.44 for Q4 2024.

  • For Q4 2024, EPS (Weighted Average and Diluted) fell 7061.7% year-over-year to -$65.44; the TTM value through Dec 2024 reached -$68.01, down 3437.19%, while the annual FY2025 figure was -$11.93, 82.46% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2024 was -$65.44 at Adial Pharmaceuticals, down from -$0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.94 in Q4 2023 and bottomed at -$65.44 in Q4 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.48 (2022), against an average of -$6.33.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 136.92% in 2023 before it tumbled 7061.7% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.55 in 2022, then surged by 136.92% to $0.94 in 2023, then tumbled by 7061.7% to -$65.44 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's EPS (Weighted Average and Diluted) are -$65.44 (Q4 2024), -$0.07 (Q3 2024), and -$0.31 (Q2 2024).